» Articles » PMID: 27408923

Characterization Data on the Topical Carrier DDC642

Overview
Journal Data Brief
Date 2016 Jul 14
PMID 27408923
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

This article contains original data, figures and methods used in the characterization of the liposomal carrier 'DDC642' for topical applications, described in "An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: proof-of-concept in the treatment of psoriasis" (Desmet et al., 2016) [1]. Several elastic liposomal formulations have been evaluated for their ability to encapsulate and deliver RNA interference (RNAi) molecules to cultured primary skin cells. The efficiency and effectiveness of these liposomes were compared to that of our previously characterized liposomes, the 'SECosomes' (SEC) (Geusens et al., 2010) [2]. After selection of a potential superior carrier, based on encapsulation and transfection efficiency data (Desmet et al., 2016) [1], the selected DDC642 liposomes were characterized more in-depth. Herein, a detailed characterization of the DDC642 liposome and RNAi-loaded lipoplexes is given, including the matching protocols.

Citing Articles

Editing via RNA -Splicing in RDEB-Derived Skin Equivalents.

Liemberger B, Bischof J, Ablinger M, Hainzl S, Murauer E, Lackner N Int J Mol Sci. 2023; 24(5).

PMID: 36901775 PMC: 10002491. DOI: 10.3390/ijms24054341.


Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa.

Ablinger M, Lettner T, Friedl N, Potocki H, Palmetzhofer T, Koller U Int J Mol Sci. 2021; 22(7).

PMID: 33805154 PMC: 8036626. DOI: 10.3390/ijms22073326.


Advances in the Application and Impact of MicroRNAs as Therapies for Skin Disease.

Lawrence P, Ceccoli J BioDrugs. 2017; 31(5):423-438.

PMID: 28875300 PMC: 5610219. DOI: 10.1007/s40259-017-0243-4.

References
1.
De Spiegeleer B, Boonen J, Malysheva S, Diana Di Mavungu J, De Saeger S, Roche N . Skin penetration enhancing properties of the plant N-alkylamide spilanthol. J Ethnopharmacol. 2013; 148(1):117-25. DOI: 10.1016/j.jep.2013.03.076. View

2.
Desmet E, Bracke S, Forier K, Taevernier L, Stuart M, De Spiegeleer B . An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: Proof-of-concept in the treatment of psoriasis. Int J Pharm. 2016; 500(1-2):268-74. DOI: 10.1016/j.ijpharm.2016.01.042. View

3.
Bracke S, Desmet E, Guerrero-Aspizua S, Tjabringa S, Schalkwijk J, Van Gele M . Identifying targets for topical RNAi therapeutics in psoriasis: assessment of a new in vitro psoriasis model. Arch Dermatol Res. 2013; 305(6):501-12. DOI: 10.1007/s00403-013-1379-9. View

4.
Dynoodt P, Mestdagh P, Van Peer G, Vandesompele J, Goossens K, Peelman L . Identification of miR-145 as a key regulator of the pigmentary process. J Invest Dermatol. 2012; 133(1):201-9. DOI: 10.1038/jid.2012.266. View

5.
Moiset G, Cirac A, Stuart M, Marrink S, Sengupta D, Poolman B . Dual action of BPC194: a membrane active peptide killing bacterial cells. PLoS One. 2013; 8(4):e61541. PMC: 3631201. DOI: 10.1371/journal.pone.0061541. View